放化疗联合度伐利尤单抗治疗切除后非小细胞肺癌局部区域复发
这项多中心回顾性研究纳入24例非小细胞肺癌术后局部区域复发并接受放化疗联合度伐利尤单抗治疗的患者,12、18、24个月无进展生存率分别为68.7%、45.8%、34.3%,12个月和18个月生存率分别为91%和82.8%。作者提出该策略可能延长体能状态良好患者的复发后生存。
要点
- 24例术后局部区域复发NSCLC患者接受放化疗联合度伐利尤单抗治疗。
- 12、18、24个月无进展生存率分别为68.7%、45.8%、34.3%。
- 12个月和18个月生存率分别为91%和82.8%,共3例死亡。
核心结论
- 作者提出,对于体能状态良好、术后出现局部区域复发的非小细胞肺癌患者,放化疗联合度伐利尤单抗的策略可能延长复发后生存。
研究设计与样本
- 多中心回顾性研究,纳入接受非小细胞肺癌手术切除后出现局部区域复发并接受放化疗联合度伐利尤单抗治疗的患者。
主要发现
- 共24例患者符合纳入标准,诊断时平均年龄65岁(范围47-78),男性占58.3%。
- 12个月无进展生存率为68.7%,18个月无进展生存率为45.8%,24个月无进展生存率为34.3%。
- 共3例死亡,12个月生存率为91%,18个月生存率为82.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: tumor recurrence after NSCLC surgical resection is the most common cause of treatment failure that sharply reduces the patient's life expectancy. The optimal treatment strategy for loco-regional recurrences developing after surgical resection in patients with non-small-cell lung cancer (NSCLC) is not established yet. This report aims to describe the pattern of relapse, PFS, and OS in patients treated with radio-chemotherapy and durvalumab for loco-regional relapse after surgery. METHODS: We conducted a multicenter, retrospective study including subjects who underwent surgical resection for NSCLC and were treated with Pacific protocol after loco-regional relapse. RESULTS: Twenty-four patients met the inclusion criteria. At the time of diagnosis mean age was 65 years (range 47-78), the majority being male (58.3%). The 12-month progression-free survival rate was 68.7%, the 18-month progression-free survival rate was 45.8%, and the 24-month progression-free survival rate was 34.3%. There were three deaths: the 12-month survival rate was 91%, and the 18-month survival rate was 82.8%. CONCLUSIONS: In this article, we propose a treatment strategy that might prolong post recurrence survival in patients with good performance status experiencing loco-regional relapse after surgery.
引用
- Borghetti P, Imbrescia J, Volpi G, et al. Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC. Radiat Oncol. 2022. PMID: 35842660. doi:10.1186/s13014-022-02084-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。